Trevi Therapeutics Raises $150M for Haduvio Clinical Trials

0:00Trevy Therapeutics, the new Haven Biofarmer crew, just filed to raise $150 million in a public stock offering to fuel there. Chronic cough drug, Hadovio, they're putting $11.6 million shares on the block at $13 each, on Nasdaq, with underwriters holding a 30-day option for. Another $22.5 million worth, pushing potential proceeds higher. The cash mainly funds clinical trials for Hadovio and lung conditions like idiopathic pulmonary fibrosis, plus some corporate needs losses are. Shrinking too, with a fourth quarter 2025 net loss, have $8.3 million versus $11.4 million last year. Full year 2025 loss hit, $42.8 million, better than $47.9 million in 2024, and they closed. With $188.3 million in cash and securities, CEO Jennifer Good says this infusion catapults their war chest past $300 million, stretching the runway clean through $20.29 as Phase III

1:05Trials Gear Up next year. Stay informed with Hartford News today, AI-powered updates. I'm Corey with the story.